In this exploratory study, we examined the association of SNPs in VEGF-A, VEGFR1, and VEGFR2 with prognosis, benefit from bevacizumab treatment and hypertension in patients receiving capecitabine alone and in combination with bevacizumab (± mitomycin C) in the MAX clinical trial. The gene discussed is VEGFA; the disease is hypertensive disorder.